NCT02956837 - A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women | Biotech Hunter

Enrollment

406

Participants

Timeline

Start Date

November 10, 2016

Primary Completion Date

August 30, 2017

Study Completion Date

February 5, 2018

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSV Vaccine (GSK3003891A) formulation 1

Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

BIOLOGICAL

RSV Vaccine (GSK3003891A) formulation 2

Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

BIOLOGICAL

RSV Vaccine (GSK3003891A) formulation 3

Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

DRUG

Placebo (Formulation buffer S9b)

A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

Trial Locations (8)

GSK Investigational Site, Ghent

GSK Investigational Site, Tallinn

GSK Investigational Site, Hanover

GSK Investigational Site, Goch

GSK Investigational Site, Tartu

GSK Investigational Site, Clermont-Ferrand

GSK Investigational Site, Paris

GSK Investigational Site, Würzburg